COMPANY . MANAGEMENT

Peter Stadler, Ph.D., CEO, Managing Director

Dr. Peter Stadler co-founded ARTEMIS in June 1998 and is ever since Managing Director (CEO) of the company. Peter has managed two ARTEMIS sites in Germany, was responsible for raising approximately 30 Mio. EUR in two rounds of financing, and led the merger of ARTEMIS and Exelixis. He is a former executive of Bayer AG where he held various positions in Germany and the US in the Central Research Department, the Corporate Staff Division, and the Pharmaceuticals Business Group over a period of 21 years. In his final position he was the Head of Pharma-Biotechnology at Bayer AG. As a leading figure in the German biotechnology industry he has been or still is a member of the board of various industry- or science-related organizations and an advisor to the German government. From 2003 through 2006 he was Chairman of the Board of the German Association of Biotech Industries (DIB, Frankfurt). He holds a Ph.D. in Organic Chemistry from the University of Hamburg and is an Honorary Professor of Biotechnology of the University of Bielefeld, Germany. He served for five years as a Member of the Board of Exelixis, Inc., South San Francisco and presently is Chairman of NewlabBioquality AG, Erkrath, Germany. In 1997 he was nominated member of the Royal Academy of Medicine of Spain, Madrid.

Paul Rounding, Ph.D., Managing Director, Business Development & Operations

Paul Rounding Ph.D. is Managing Director of TaconicArtemis with primary responsibilities for commercial, IP, business development and project management activities within the company. He joined ARTEMIS in January 2000 as head of business development and made major contributions to establishing portfolio of licenses and patents in mouse genetics which form the basis of the current business. Following the acquisition of ARTEMIS by Exelixis in 2001, Paul was intimately involved in developing and implementing ARTEMIS' independent commercial strategy; he identified and closed commercial collaborations with major commercial partners, such as Merck Inc., ITI Life Sciences, Bayer AG, Schering AG and BMS. Together with Prof. Stadler, Paul managed the expansion of the company and has made significant contributions to developing the "Invivogen" concept to guide the next phase of company development. Prior to joining ARTEMIS, Paul obtained his Ph.D. in Physiology from University of London and worked with Bayer AG for 17 years. During this time he occupied positions in drug discovery research in the UK and Germany during which time he contributed to the in vivo testing of respiratory and cardiovascular drugs. In 1994 he became head of Bayer cardiovascular technology licensing in both Germany and Berkeley USA. In 1996 he moved to the licensing department, with responsibility for creating and implementing a licensing strategy for Bayer's South East Asia and middle East regions, during this time he negotiated and closed more than 50 product licensing deals. From 1998 until the end of 1999 Paul was project manager for Ciprofloxacin and made a significant contribution to the line extension strategy for this product.

Oliver Radtke, CPA (Certified Public Accountant), Director Finance

Oliver Radtke joined ARTEMIS in 2007 and leads the Finance department. In 1997 he graduated as an MBA (Master of Business Adminstration) at the University of Cologne. He started his career as an auditor with Arthur Andersen in 1998 where he was responsible for audits of both German and US-GAAP clients as well as due diligence projects. During this time he acquired the degree of a CPA in the state of Georgia/USA in the year 2000. In 2001 he switched to Ortho-Biotech, the biotechno-logical division of Janssen-Cilag GmbH and assumed there the function of a Controller. In this role he focused on both financial planning and analysis and served as a member of the SOX core team assuring compliance with Sarbanes Oxley Act Section 404. He left the company in 2005 and joined GE Medical Systems GmbH & Co. KG as Controller Central Europe. Here he was responsible for seven companies of the Central Region and the management of several remote teams in India, Hungary and Germany. Besides his scope included overall responsibility for the Financial Statements under US-GAAP and German GAAP as well as for SOX compliance of the German GE Medical Systems company. Additionally he participated in several special projects ranging from introduction of a report system for Intrastat purposes to leading a restructuring exercise with the goal to create a lean Accounts Payable process.

Manfred Stelzer, Manager Human Resources

Manfred Stelzer is responsible for Human Resources at TaconicArtemis GmbH. Manfred joined ARTEMIS in 2003 as a Manager for Finance, Controlling and Human Resources. He maintained this position until March 2007. At this point in time ARTEMIS had reached a size in headcount which required a separation of HR and Finance. Ever since Manfred is the Head of Human Resources. Subsequent to his education as an industrial clerk Manfred was trained to become a qualified accountant and a personell specialist. He worked with Xerox Ltd. in Ireland as a team leader in Finance for the German market and with a Social Research Institute in Cologne as accountant and HR-specialist. Before that he worked as an accounting clerk with Toys “R” Us in Cologne for the German and Swiss market and had his training with ITT Richter Chemie-Technik in Kempen.

Michael Schoor, Ph.D., Director, Scientific Project Management

Dr. Michael Schoor is responsible for the management of major TaconicArtemis customer projects, ensuring that projects adhere to strict timelines and that progress of projects is promptly and fully communicated to our customers. Michael is also a point person for scientific discussion of new projects with existing and potential future customers. He joined ARTEMIS in early 2000 after completing five years of postdoctoral work at Stanford University, School of Medicine, in the laboratory of Dr. David Kingsley to examine bone and joint development using mutant and BAC transgenic mice. He received his Ph.D. in Genetics at the University of Cologne in the laboratory of Prof. Achim Gossler at the Max Planck Institute in Cologne, where he used enhancer trap screens and knock out mice to elucidate the function of genes in skeletal development.

Gunther Kauselmann, Ph.D., Head of Molecular Biology,

Dr. Gunther Kauselmann leads the molecular biology department at TaconicArtemis with responsibility for data mining, design, construction and sequencing of targeting vectors, analysis and validation of ES cell clones and verification of genetically engineered mice. Gunther has been with ARTEMIS since 1998. Prior to joining ARTEMIS he was a Postdoctoral Fellow in the laboratory of Dr. Dietmar Kuhl at the Center for Molecular Neuroscience Hamburg (ZMNH) working on the identification of genes involved in learning and memory. He holds a Ph.D. in Biology from the University of Hamburg.

Branko Zevnik, Ph.D., Associate Director, Head of the Applied Genetics Department

Dr. Banko Zevnik leads the department of Applied Genetics. This includes the responsibility for Embryonic Stem Cell Culture and Microinjection at TaconicArtemis. Branko joined ARTEMIS in early 2000. Prior to this he headed the transgenic facility at the Institute for Cell Biology in Essen for four years. He completed his post-doctoral work at the GSF Research Center, Munich, Germany, in the laboratory of Prof. Rudi Balling on induction gene trap in embryonic stem cells. His Ph.D. in Genetics was received in 1994 from the University of Freiburg, on the targeted inactivation of Oct-4, a transcription factor required for pluripotency of embryonic stem cells. The Ph.D. thesis was performed from 1992 - 1994 in the laboratory of Prof. Austin Smith, Institute for Stem Cell Research, Edinburgh, UK.

Gloria Esposito Ph.D., Senior Manager, Scientific Project Management

Dr. Gloria Esposito joined the ARTEMIS Scientific Management Team in 2006. Gloria received her Ph.D. in Genetics and Molecular Biology in 1996 from the University of Rome "La Sapienza". She performed her thesis at IRBM-Merck in Pomezia (Rome), where she contributed to the construction and characterization of Antibody Phage-Display libraries. In 1996, she moved to the laboratory of Prof. Klaus Rajewsky at the University of Cologne as a postdoctoral fellow to study lymphocyte development and antibody maturation by exploiting gene targeting technologies. Gloria joined Organon Pharmaceuticals in Oss (The Netherlands) in 2002 where she was responsible for the in vivo characterization of novel drug target candidates using transgenic mouse models. At TaconicArtemis, Gloria manages projects to generate genetically modified mice and is actively involved in the corresponding scientific discussions with the TaconicArtemis customers. Besides her critical role in the realization of existing projects, she is involved in the identification and acquisition of new business opportunities for TaconicArtemis.

Holger Kissel, Ph.D., Senior Manager, Scientific Project Management

Dr. Holger Kissel joined the Scientific Project Management team at ARTEMIS in 2005. He conducted his Ph.D. thesis at the Memorial Sloan Kettering Cancer Center in New York using knock-in point mutations for the study of signal transduction pathways in vivo. In 2000, he joined The Rockefeller University and conducted his postdoctoral work first with Pofessor Titia de Lange in the Laboratory Cell Biology and Genetics. Then 2002 Holger joined Dr. Hermann Steller in the Laboratory of Apoptosis and Cancer Biology. His specific interest focused on the use of knock out mouse models for the study of caspase activation and the deregulation of apoptotic signaling during cancer development. At TaconicArtemis he oversees the generation of genetically modified mouse models, is involved in scientific consulting for TaconicArtemis customers and evaluates new scientific concepts and technologies for integration into the ArteMice platform.

Nico Scheer, Ph.D., Research Group Leader ADME/Tox

Dr. Nico Scheer has responsibilities for the development of humanized mice relevant for the early and predictive detection of ADME parameters. Nico joined ARTEMIS in January 2001 from the University of Cologne. He received his Ph.D. in Developmental Biology in 2000 in the laboratory of Dr. Jose Antonio Campos-Ortega on the establishment and functional application of the GAL4/UAS system in zebrafish. Before joining the mouse team Nico was responsible for technology development and transgenesis in zebrafish within ARTEMIS.

Jost Seibler, Ph.D., Head of Technology Development and RNAi Research

Dr Jost Seibler leads the group dedicated towards the development of novel technologies for inducible expression and repression of genes, for targeted transgenesis and for mouse disease models. Inspiring and implementing new concepts is his daily business as well as advising scientists and external customers. Moreover he has established and is responsible for the RNAi custom project group. Jost joined ARTEMIS in March 2000 from the National Research Center for Biotechnology in Braunschweig (GBF). There he developed recombinase based technologies for genetic engineering of the ES cell genome, including a system for the efficient exchange of gene expression cassettes. He received his Ph.D. in 1999 from the TU-Braunschweig. At ARTEMIS he has contributed significantly towards development of proprietary knock out systems and other key technologies.

Chris Schleiermacher, Ph.D., Head of Computational Biology & IT

Dr. Chris Schleiermacher is responsible for software and database development, data mining concepts and IT infrastructure in the Computational Biology / IT department which he joined in 2001. Chris received his Ph.D. from the University of Bielefeld in the Faculty of Technology in 2001. The theme of his Ph.D. thesis was in the field of whole genome analysis. Chris developed some well known software titles like GeneFisher and REPuter at this time.

Stefan Spiess, Ph.D., Manager IT

Dr. Stefan Spiess joined ARTEMIS 2006 as the responsible person for the IT Infrastructure. Stefan finished his Master in Chemistry 1994 at the University Freiburg. In 1999 he achieved his Ph.D. in Molecular Biology with the University Hamburg at the Zentrum für Molekulare Neurobiologie. Subsequent to his studies he changed the subject and started his career in the area of Information Technology. Stefan has worked for ARTEMIS as an IT Specialist until 2004. Between that and 2006 Stefan worked for the Life and Brain Center in Bonn.

Frieder Schwenk, Ph.D., Principal Scientist

Dr. Frieder Schwenk is a highly renowned expert in the field of mouse genetics and remains associated with TaconicArtemis in a part-time capacity. Frieder was the Head of the Technology Department at ARTEMIS Pharmaceuticals till October 2003. He joined ARTEMIS in 1998 from the laboratory of Dr. Klaus Rajewsky, where he made a major contribution to the pioneering work on the conditional gene targeting strategy. Frieder received his Ph.D. in Genetics in 1997 from the University of Cologne on the development of the first system for temporally and spatially regulated gene targeting in mice. Frieder is a co-author for a respective publication in “Science”. He is a Professor for Molecular Biology and Physiology at the University of Applied Science in Gelsenkirchen, Germany.

Vincent Beuger, Ph.D., Research Scientist

Dr. Vincent Beuger leads the RNAi custom project group at TaconicArtemis with responsibilities for data mining, construction and sequencing of shRNA-vectors, qPCR-analysis , validation of ES cell clones, and verification of genetically engineered mice. Vincent has been with ARTEMIS since 2006. Prior to joining ARTEMIS he was a Postdoctoral Fellow in the laboratory of Dr. Helmut Burtscher at Roche Diagnostics GmbH in Penzberg (Germany) working on the improvement of toxicity of therapeutic antibodies. Dr. Beuger received his Ph.D. in Molecular Biology in 2004 from the University of Marburg on the exploration of the cMyc-Miz interaction in the laboratory of Prof. Dr. Martin Eilers.

Nathalie Uyttersprot, Ph.D., Research Scientist

Dr. Nathalie Uyttersprot joined ARTEMIS in 2006 and leads the group of Vector construction and ES Cell Validation within the Dept. of Molecular Biology. Nathalie received her diploma in Chemistry at the Universite Libre de Bruxelles, Belgium. Subsequently Nathalie obtained her Ph.D. in Sciences (molecular and cellular biology) in the lab of Prof. J. E. Dumont and G. Vassart, Universite Libre de Bruxelles, Belgium on the “Role of CREB/CREM transcription factors in the cAMP-dependent mitogenic pathway of thyroid cells”. Nathalie had her postdoctoral training in the lab of Prof. K. Rajewsky at the Institute for Genetics, University of Cologne, studying the “Role of the Igbeta subunit of the B-cell receptor on the maintenance of B-lymphocytes” using mouse genetics from January 1999 until May 2002. She also worked as a research scientist and group leader in the lab of Prof. G. W. Bornkamm at the GSF, Institute for Clinical Molecular Biology and Tumor Genetics in Munich, where she was using mouse models to study the development of lymphomas from June 2002 until February 2006.